ReviewEmerging infectious diseases2002
Passive antibody administration (immediate immunity) as a specific defense against biological weapons.
Review in Emerging infectious diseases, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 163 citations in OpenAlex.
- How Can Plant-Derived Natural Products and Plant Biotechnology Help Against Emerging Viruses?International journal of molecular sciences · 2025Review
- Using Passive Antibody Therapies in the Next Pandemic.Current topics in microbiology and immunology · 2025Review
- A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19.Current topics in microbiology and immunology · 2025Review
- Antigen-Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD.Frontiers in molecular biosciences · 2022Article
- Design of a chitosan-based nano vaccine against epsilon toxin ofResearch in pharmaceutical sciences · 2021Article
- Article
- Immunological Responses to Envenomation.Frontiers in immunology · 2021Review
- Convalescent plasma therapy in patients with COVID-19.Journal of clinical apheresis · 2020Review
- Deployment of convalescent plasma for the prevention and treatment of COVID-19.The Journal of clinical investigation · 2020Review
- Production of functional recombinant cyclic citrullinated peptide monoclonal antibody in transgenic rice cell suspension culture.Transgenic research · 2019Article
- Leaf-Encapsulated Vaccines: Agroinfiltration and Transient Expression of the AntigenJournal of immunology research · 2018Article
- Article
- Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates.The American journal of tropical medicine and hygiene · 2016Article
- Potent In Vitro and In Vivo Activity of Plantibody Specific for Porphyromonas gingivalis FimA.Clinical and vaccine immunology : CVI · 2016Article
- Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies.Frontiers in immunology · 2016Review
- A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Current medicinal chemistry · 2016Review
- A Novel Chimeric Anti-PA Neutralizing Antibody for Postexposure Prophylaxis and Treatment of Anthrax.Scientific reports · 2015Article
- Characterization of a lipopolysaccharide-targeted monoclonal antibody and its variable fragments as candidates for prophylaxis against the obligate intracellular bacterial pathogen Coxiella burnetii.Infection and immunity · 2014Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The potential threat of biological warfare with a specific agent is proportional to the susceptibility of the population to that agent. Preventing disease after exposure to a biological agent is partially a function of the immunity of the exposed individual. The only available countermeasure that can provide immediate immunity against a biological agent is passive antibody. Unlike vaccines, which require time to induce protective immunity and depend on the host's ability to mount an immune response, passive antibody can theoretically confer protection regardless of the immune status of the host. Passive antibody therapy has substantial advantages over antimicrobial agents and other measures for postexposure prophylaxis, including low toxicity and high specific activity. Specific antibodies are active against the major agents of bioterrorism, including anthrax, smallpox, botulinum toxin, tularemia, and plague. This article proposes a biological defense initiative based on developing, producing, and stockpiling specific antibody reagents that can be used to protect the population against biological warfare threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.